Atrial Functional Mitral Regurgitation: JACC Review Topic of the Week.

atrial fibrillation functional mitral regurgitation heart failure with preserved ejection fraction mitral annular dilatation mitral annulus secondary mitral regurgitation

Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
21 05 2019
Historique:
received: 04 01 2019
revised: 15 02 2019
accepted: 18 02 2019
entrez: 18 5 2019
pubmed: 18 5 2019
medline: 31 3 2020
Statut: ppublish

Résumé

Unlike secondary mitral regurgitation (MR) in the setting of left ventricular (LV) disease, the occurrence of functional MR in atrial fibrillation (AF) and/or heart failure with preserved ejection fraction (HFpEF) has remained largely unspoken. LV size and systolic function are typically normal, whereas isolated mitral annular dilation and inadequate leaflet adaptation are considered mechanistic culprits. Moreover, the role of left atrial and annular dynamics in provoking MR is often underappreciated. Because of this peculiar pathophysiology, atrial functional MR benefits from a different approach compared with secondary MR. Although both AF and HFpEF-two closely related disease epidemics of the 21st century-are held responsible, current guidelines do not emphasize the need to differentiate atrial functional MR from (ventricular) secondary MR. This review summarizes the prevalence and prognostic importance of atrial functional MR, providing mechanistic insights compared with those of secondary MR and suggesting potential therapeutic targets.

Identifiants

pubmed: 31097168
pii: S0735-1097(19)34554-1
doi: 10.1016/j.jacc.2019.02.061
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2465-2476

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Sébastien Deferm (S)

Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium; Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.

Philippe B Bertrand (PB)

Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium; Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.

Frederik H Verbrugge (FH)

Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium; Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.

David Verhaert (D)

Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium.

Filip Rega (F)

Department of Cardiac Surgery, Cardiovascular sciences, Leuven University Hospital, Leuven, Belgium.

James D Thomas (JD)

Department of Cardiology, Northwestern University, Bluhm Cardiovascular Institute, Chicago, Illinois.

Pieter M Vandervoort (PM)

Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium; Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium. Electronic address: pieter.vandervoort@zol.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH